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ABSTRACT 
Mycobacterium ulcerans is an environmental organism which is responsible for 
the disease Bunili ulcer, a resistant, severe, necrotizing skin disease. Bunlli ulcer occurs 
in West and Central Africa, Australia, and Asia, but it appears to be increasing 
significantly in West Africa. M ulcerans produces a polyketide-derived macrolide, 
mycolactone, which is required for virulence. Mycobacterium is a large genera with 
diverse species. Most of these species are non-pathogens present in soil and water. 
Although mycolactone production has been demonstrated in M ulcerans from many 
countries, a search for mycolactone in other Mycobacterium species has not been 
undertaken. We have extracted polyketides from 46 Mycobacterium isolates, analyzed 
them with thin-layer chromatography (TLC), and tested them in a murine fibroblast cell 
line (L929) to investigate whether mycolactone or a similar lipid are produced by 
Mycobacterium species other than M ulcerans. In these studies acetone soluble lipids 
(ASL) were prepared from a chloroform-methanol extract obtained from 4 fast growing 
species and 25 slow growing species of Mycobacterium. Among the slow growing 
species were 16 uncharacterized, species of Mycobacterium isolated from aquatic sources 
in areas endemic to M ulcerans infection. Biochemical and cell culture assays of these 
lipids showed that whereas several strains of mycobacteria studied produced toxic lipids 
when tested in cell culture, none made mycolactone. Whereas mycolactone is toxic at 
picogram amounts, none of the lipids tested from other Mycobacterium species were 
active at less than 10 µg amounts, and none produced· a cellular phenotype consistent with 
mycolactone activity. Two species of Mycobacterium, M scrofulaceum and M kansasii, 
contained lipids cytopathic to L929 fibroblasts at a concentration of less than 20 µg/µl. 
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In addition, eight of the environmental isolates contained cytopathic lipids. Analysis of 
the 16S rRNA sequence of these 8 environmental isolates ofmycobacteria with 
cytopathic ASLs suggest that these 8 environmental isolates are novel species of 
Mycobacterium. Results from these studies show that although production of cytopathic 
lipids is relatively common among Mycobacterium species, the production of 
mycolactone appears so far to be restricted to M ulcerans. 
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1. INTRODUCTION 
I. Buruli Ulcer Disease: 
Mycobacterium ulcerans is the causative agent ofBuruli ulcer, an emerging 
infection in West Africa. The first clinical description of Buruli ulcer was reported in 
Australia in 1937 and designated the "Bairnsdale ulcer," however, the ulcers were 
thought to be due to Mycobacterium tuberculosis or Mycobacterium /eprae (1). It was 
not until 1948 that the association between the disease and M ulcerans was established. 
However, Sir Albert Cook had described the disease, which had been well known in 
Africa before this in 1897 (35). It is now recognized that epidemics of Buruli ulcer have 
occurred for over 100 years and that M ulcerans is endemic in much of West and Central 
Africa. Buruli ulcer is now the third most common mycobacterial disease in non­
immunocompromised people behind tuberculosis and leprosy (37). 
The disease is characterized by progressive, severe necrotizing skin lesions that 
do not respond to antimicrobial therapy and require surgical excision as treatment (37) 
(Figure 1 ). Most of these lesions occur on the extremities ( 14 ). The first stage of disease 
(preulcerative stage) is indicated by a papule or a non-tender nodule or plaques with large 
areas of indurated skin. At later stages these lesion may progress to a plaque or 
edematous form. Histopathology of Buruli ulcer shows necrosis of the subcutaneous fat 
and vascular damage, which results in sloughing and secondary ulceration of the 
overlying skin with undermined edges (37) (Figure 2). Massive clusters of extracellular 
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Figure 1. Ulcerative lesion of Buruli ulcer on the upper right arm of a male. 
Adapted from van der Werf, 1999. 
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Figure 2. Stages of Buruli ulcer disease. From van der W erf, 1999. 
acid-fast bacteria can be found within the necrotic tissue; however, the necrosis of the 
tissue spreads beyond these clusters of bacteria. The presence of tissue damage which 
extends beyond the presence of the organisms was the first clue that M ulcerans might 
produce a secreted toxin (4). A distinct feature of Buruli ulcer is that organisms are 
found extracellularly, unlike all other my co bacterial infections, such as leprosy and 
tuberculosis, where organisms are found intracellularly (14, 35). 
Buruli ulcer is a rural disease with wide distribution. Cases have been identified 
in Africa, Asia, South America, and low-lying marshy regions in Australia. Lesions 
clinically identical to those in humans have also been seen in koalas and ringtail possums 
in Australia (39). The disease has been described in more than 30 countries and an 
unexplained recent increase in the occurrence of the disease has occurred in West Africa 
(7). 
M ulcerans is an acid-fast, slow growing member of the environmental 
mycobacteria. Like M leprae and M marinum, M ulcerans does not grow at 3 7°C and 
has an optimal growth temperature of 31-33°C (35). The mode of transmission of M 
ulcerans is unknown. Epidemiological evidence defines proximity to slow-moving water 
as a previous risk factor for Buruli ulcer, and the bacterium cannot enter through intact 
skin (35). Recent evidence has implicated the involvement of aquatic insects as potential 
vectors in the infection process. Portaels et al. found several species of swamp insects 
that were PCR positive for M ulcerans. Furthermore, they proposed that water-filtering 
organisms concentrate the bacteria and pass them on to aquatic predators, which pass the 
disease on to humans by biting (30). Recently, Marsollier et al. was able to infect 
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aquatic insects (Naucoridae) with M ulcerans and transfer this infection to laboratory 
mice through biting. Furthermore, they were able to detect M ulcerans in the salivary 
glands of these aquatic insects as well as others (23). 
II. Identification of M. ulcerans: 
Molecular diagnosis of M ulcerans is possible through polymerase chain reaction 
(PCR) of two insertion sequences (ISs), IS2404 and IS2606, which have high specificity 
for M ulcerans. IS elements do not have an essential function for the cell, but they do 
have the capability of promoting rearrangements, sequestering genes, and modifying gene 
expression. These IS elements are found in M ulcerans in at over 50 copies each. 
Furthermore, these IS elements are nearly unique to M ulcerans, with the exception of 
the identification of IS2606 in Mycobacterium lentiflavum (34 ). Previous diagnostic 
methods relied on staining the necrotic tissue samples from the lesion and identifying the 
presence of extracellular acid-fast bacilli (37). The use of these PCR probes as an 
identification for M ulcerans is highly sensitive and specific. 
III. Polyketides: 
Polyketides are biologically active lipid molecules which have important 
medicinal activities such as antibiotic, anticancer, antifungal, antiparasitic, and 
immunosuppressive properties (33). Polyketides are related by a common method of 
biosynthesis, not common structural features. Polyketide biosynthesis is very similar to 
fatty acids biosynthesis. In both cases synthesis is based upon repeated condensations of 
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acyl groups onto a growing carbon chain. The enzymes responsible for polyketide 
synthesis, polyketide synthases (PKS), are classified into type I or type II based on how 
closely they mimic fatty acid synthases for vertebrates (type I) or for bacterial and plant 
(type II). However, polyketides are much more diverse than fatty acids because synthesis 
of a single molecule may utilize several different extender units. In addition, in some 
cases (type I PKSs) post-PKS modifications occur (27). Many structural subgroups of 
polyketides exist, and these include aromatics, macrolides, polyethers, and polyenes 
(38). Macrolides are formed from branched-chain fatty acids that cyclize to form a 
lactone ring. Erythromycin, produced by Saccharopolyspora erythraea, is a polyketide 
antibiotic belonging to the macrolide class (18). M ulcerans produces a polyketide­
derived macrolide, mycolactone, which is required for the organism's virulence (10). 
IV. Mycolactone Toxin: 
Mycolactone is a 12-membered macrolide ring formed by joining two polyketide 
chains to produce a hybrid polyketide. Mycolactone exists as a mixture of two isomeric 
compounds, mycolactone A and B which occur in about a 3 :2 ratio, with mycolactone A 
being the major compound (13) (Figure 3). One of these two polyketide chains which 
form mycolactone A/B undergoes cyclization to form the 1 2-membered core lactone ring 
(8). Mycolactone is a relatively polar lipid and is obtained by chloroform-methanol (2: 1 ,  
vol/vol) extraction of culture filtrate or bacteria. The partially purified extract is enriched 
for mycolactones by adding ice-cold acetone, a process which removes the phospholipids 
and leaves the acetone soluble lipids (ASL) (9). 
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Figure 3. Mycolactone isomers: mycolactone A, structure 1, and mycolactone B, 
structure 2. Adapted from Gunawardana, 1999. 
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Mycolactone exhibits a specific cytopathic effect on murine L929 fibroblasts, 
characterized by cell rounding within 24 hours, cell cycle arrest in the G0/G1 phase of the 
cell cycle by 36 hours, followed by apoptosis in 72 hours. Injection of guinea pigs with 
mycolactone produces a lesion with the same characteristics as M ulcerans infection, 
namely, a painless, necrotic, non-inflammatory lesion, whereas, a mycolactone negative 
mutant of M ulcerans fails to develop a lesion on guinea pigs (10). This evidence 
clearly indicates that mycolactone plays a major role in the development of these necrotic 
lesions seen with Buruli ulcer. 
For M ulcerans, Trudeau Mycobacterial Culture Number 16 15, maximum 
cytopathic activity is associated with an ultraviolet (uu )-active, light yellow component 
with a ratio to front value (Rr) of 0.23 in a solvent system of chloroform-methanol-water 
(90 : 10: 1 , vol/vol/vol) (10). It has recently been shown that M ulcerans 16 15  produces 
mycolactone congeners, minor species of mycolactone, in addition to mycolactone A/B 
(2). Also, it has recently been shown that mycolactones are four heterogeneous groups of 
macrolides which vary according to the geographic origin of the species of M ulcerans. 
Mycolactone A/B is the major mycolactone component of ASLs for M ulcerans 1 61 5, a 
Malaysian isolate, as well as for African isolates (24). Mycolactone A/B is a cell 
associated lipid that produces a peak at mlz 765.5 [M+Nat under mass spectroscopy 
(MS) analysis (10). MS analysis of strains from different regions shows that 
mycolactone A/B is also a component of Australian strains and Asian strains ASLs, but it 
is not the major component. Mycolactone C is the name given to the major species of the 
Austrailian isolates and it is indicated on MS as a peak at mlz 7 49 .5. Asian species 
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contained a major peak at mlz 781.3 on MS analysis and this molecule is termed 
mycolactone D. Finally, neither mycolactone A/B, C, or D can be detected in Mexican 
strains although ASLs of M ulcerans from Mexico exhibit typical mycolactone 
cytopathicity (24). 
A lipid component of 1615 M ulcerans ASLs, termed the core lactone, exhibits a 
cytopathic phenotype similar to that of mycolactone A/B on L929 cells. This core 
lactone is believed to be a precursor molecule for mycolactone. The core lactone is 
10,000 times less active than mycolactone A/B. MS analysis of the core lactone shows it 
to be a peak at mlz 447.4 [M+Nat (24). 
Inflammatory cells are conspicuously lacking from Buruli ulcer lesions due to the 
presence of mycolactones. Several studies have shown that mycolactone is an 
immunosuppressive molecule which suppresses a T-cell mediated immune response as 
well as the acute inflammatory response. Antibody responses to the organism can be 
detected although antibodies to mycolactone are not (12). Unlike most environmental 
mycobacteria, the disease is not associated with infection with human immunodeficiency 
virus (HIV). There does not appear to be an increase in Buruli ulcer disease seen among 
patients with HIV. Furthermore, patients infected with both HIV and Buruli ulcer disease 
do not have clinical presentations that are different from non-immunocompromised 
patients (26). 
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V. Management of Disease: 
Surgical excision of the lesion is so far the only effective means of treatment. 
Excision of all of the necrotic tissue as well as some of the healthy tissue is necessary, to 
prevent a reoccurring infection from residual M ulcerans. Skin grafting is necessary for 
repair of larger lesions, and plastic surgery or physiotherapy may be needed for extensive 
lesions. In most cases treatment of the lesions with antimycobacterial agents have been 
ineffective. Drugs such as clofazimine, an antileprosy drug, rifampicin, streptomycin, 
and dapsone are all effective against M ulcerans in vitro, but are not effective in 
combating these lesions (3 7). There is no current vaccine for the disease, although some 
evidence suggests that the bacillus Calmette-Guerin (BCG) vaccine may have a role in 
preventing the more serious forms of the disease (29). 
VI. Lipid Virulence Determinants in Mycobacterium Species: 
Lipids are important virulence determinants for many microorganisms. For 
example, the major virulence factor of Gram-negative bacteria is lipopolysaccharide 
(LPS). LPS, a major component of Gram-negative bacteria outer membranes, is a 
glycolipid which contains lipid A, the active structure moiety of LPS. Studies have 
shown that LPS is a major virulence factor of Gram-negative bacteria because purified 
LPS or chemically synthesized lipid A are able to reproduce some manifestations of 
septic shock in man and animals that is seen with Gram-negative bacterial infection (1 5). 
Mycobacterium species lack LPS as a virulence factor, but their cell walls contain many 
biologically active, complex lipid molecules. M tuberculosis contains phthiocerol 
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dimycocerosate (PDIM), a cell-wall associated, polyketide derived lipid required for 
virulence, which appears to play a role in the growth of M tuberculosis in the lungs. 
Mutants that have a disrupted synthesis of their PDIM are unable to colonize murine 
lungs ( 6). Another polyketide lipid which is a component of M leprae cell wall, phenolic 
glycolipid-1 (PGL-1) has recently been implicated as a major factor in the 
neuropathogenesis of leprosy. Recent data suggests that PGL-1 may be involved in the 
demylination process which occurs in leprosy (31 ). Recently, evidence suggests that 
other M tuberculosis polyketides play a role in the ability of M tuberculosis to cause 
persistent infection (5). 
Macrolides are a special category of polyketides that contain a lactone ring (18). 
Soil bacteria such as Streptomyces and Saccharopolyspora produce macrolides as 
secondary metabolites (19). However, mycolactone is the first known macrolide 
produced by a human pathogen and the only known macrolide to be produced by a 
Mycobacterium species (13). Genomic evidence from many Mycobacterium species has 
revealed that Mycobacterium species, like the Streptomyces species, contain many 
polyketide genes. None of these polyketide genes, however, appear capable of encoding 
a molecule as large as mycolactone. Although the M tuberculosis genome suggests that 
M tuberculosis could not produce a polyketide such as mycolactone, a systemic search 
for similar molecules in other Mycobacterium species has not been conducted (3). 
Mycolactone appears to be encoded by two polyketide enzymes, PKS Is, and we have 
recently shown that the core lactone encoded by PKS I has cytopathic activity though its 
potency is lower than that of mycolactone (24 ). Thus a Mycobacterium species that 
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contains only a polyketide synthase for the core lactone ring would still be active. In this 
study we have extracted lipids from a collection of Mycobacterium species and used 
cytopathic activity along with biochemical analysis to determine if these other 
mycobacteria make mycolactone or mycolactone related molecules. 
VII. Objective: 
Although clinical data strongly suggest that M ulcerans is the only 
Mycobacterium species which produces a secreted toxin, studies have never been 
conducted on a large number of species of Mycobacterium to determine whether 
mycolactone or related molecules are present. Two recent findings led us to investigate 
the distribution of this molecule among Mycobacterium species. First we have shown 
that mycolactone is a hybrid polyketide comprised of two polyketides. We have shown 
that the product of the PKS gene, which encode the lactone core is active at high 
concentrations (24). The production of this molecule can be detected using tissue culture 
assays. Secondly, the presence of large numbers of IS elements in M ulcerans raises the 
possibility that some or all of the genes encoding mycolactone may have been acquired 
by horizontal transfer from other bacteria (34). If these other bacteria lacked factors for 
colonization of the human host they would probably not have been detected. We were 
particularly interested in investigating whether environmental mycobacteria isolated from 
areas endemic for Buruli ulcer produced mycolactones. 
In this study ASLs of 46 isolates from 29 different species of fast and slow 
growing my co bacteria were extracted and analyzed for the presence of mycolactones. 
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Included in this study are 16 slow growing, uncharacterized, environmental isolates of 
mycobacteria, which were isolated from water in regions endemic to M ulcerans 
infection within the Democratic Republic of Congo. Although we found that several 
mycobacteria produce cytopathic lipids, the specific cytopathic phenotype produced was 
not similar to that of mycolactone. Of the mycobacteria from which cytopathic lipids 
were extracted, two pathogenic species Mycobacterium scrofulaceum and 
Mycobacterium kansasii, contained lipids that are cytopathic to L929 fibroblasts at a 
concentration of less than 20 µg/µl. Also, it was surprising to find that 8 of the Congo 
environmental isolates (CEI) also produced cytopathic polar lipids. None of these 
cytopathic lipids were as potent as mycolactone, and more importantly they all have a 
markedly different cytopathic effect on L929 fibroblasts. Furthermore, we tried to isolate 
these cytopathic lipids through the use of a chromatotron to determine if these cytopathic 
molecules could perhaps be due to a PKS for the core lactone. Two species of 
Mycobacterium, M tuberculosis and M marinum, are closely related to M ulcerans 
(36). However, neither of these species were included in this study because previous 
studies have indicated that neither M tuberculosis nor M marinum produce 
mycolactones (3, 9). 
Finally, in this study we further characterize the 8 CEI with cytopathic lipids. 
We have used 16S rRNA gene (16S rDNA) data to show that none of the CEI with 
cytopathic lipids are M ulcerans. Kirschner et al. found that the 16S rRNA gene is an 
accurate and versatile method for identifying mycobacteria (21 ). The 16S rRNA gene is 
a valuable tool in determining phylogenetic relationships because it has both conserved 
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and variable regions. These highly conserved regions remain so due to structural and 
functional constraints on the molecule. However, the variable regions are species 
specific and can therefore be used for identification of species (32). Therefore, primers 
are designed within the conserved regions of the 16S rRNA gene and used to amplify the 
variable regions. We have used primers designed by Hughes et al. to amplify two 
variable regions within mycobacteria 1 6S rRNA gene ( 16). Furthermore, we have used 
these 16S rRNA sequences to construct a phylogenetic tree based on other species of 
Mycobacterium. Furthermore, from the phylogenetic analysis of 16S rRNA sequences 
we show that these 8 uncharacterized CEI are new species of Mycobacterium, none of 
which are closely related to M ulcerans. 
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2. MATERIALS AND METHODS 
I. Eukaryotic Cell Culture: 
L929 murine fibroblast cells (ATCC CCL 1 )  were purchased from the American 
Type Culture Collection and passaged in Dulbecco modified Eagle medium 
supplemented with 5% heat-inactivated calf serum (Gibco BRL, Grand Island, New 
York) 
II. Bacterial Culture: 
All characterized species of Mycobacterium tested were obtained from the 
Trudeau Mycobacterial Culture Collection (TMCC) (National Institute of Health, 
Bethesda, Maryland) which had been stored at -80°C. Environmental mycobacteria were 
isolated from the Democratic Republic of Congo, Africa and were given as a gift from 
Francoise Portaels (Institute of Tropical Medicine, Antwerp, Belgium). These Congo 
environmental isolates (CEI) were received on Lowenstein-Jenson slants. Preliminary 
testing on these CEI had been done by Portaels (28). All mycobacteria tested were 
grown without shaking in Middlebrook 7H9 medium (Difeo, Detroit, Michigan) 
supplemented with 10% Middlebrook oleic acid, bovine serum albumin, dextrose, and 
catalase enrichment (OADC supplement) at 37°C or 32°C (for CEI) in l 75-cm2 tissue 
culture flasks (Falcon). 
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III. Preparation of Acetone Soluble Lipids (ASL): 
Extraction of ASLs from mycobacteria was performed as previously described 
(9). Briefly, 200 ml from late log phase cultures of all mycobacteria tested (TMCC and 
CEI) were centrifuged to pellet the bacteria. The supernatant was poured off, and the 
bacterial pellet was allowed to dry in an Isotemp Vacuum Oven (Model 280A; Fischer 
Scientific, Pittsburgh, Pennsylvania) at 65°C and 20 mHg. After drying, the bacterial 
pellet dry weight was determined using the Metler Toledo AT20 (Metler Toledo, 
Greifensee, Switzerland). The dried pellet was extracted with chloroform-methanol (2:1 , 
vol/vol) for 2 h at room temperature. Cultures were once again spun to pellet the 
bacterial debris and separate the organic matter. The organic layer was removed and 
dried down with nitrogen (Pierce Reacti-Therm heating module; Rockford, Illinois) at 
60°C and resuspended in ice-cold acetone. 
IV. Separation and Analysis of ASLs by TLC: 
Samples were analyzed by silica thin-layer chromatography (TLC) plates 
(Allteeh, Deerfield, Illinois) using a solvent system of chloroform-methanol-water 
(90: 10: 1 ,  vol/vol/vol) and lipids were visualized using eerie sulfate-ammonium 
molybdate in 2 M sulfuric acid stain as previously described (9). Briefly, 1 g of eerie 
sulfate hydrate (yellow salt) and 25 g of ammonium molybdate ( colorless salt) are added 
to 450 ml of water. While stirring, 50 ml of concentrated sulfuric acid is added to the 
mixture and the mixture is stirred for 1 h at room temperature. The ASL weight was 
determined using the Metler Toldeo AT20 (Metler Toledo) scale. For the cytopathicity 
16  
assays, all samples were resuspended in 100% ethanol. 
V. Cytopathicity Assays: 
L929 cells were plated at 6 x 103 cells/well in 96-well tissue culture plates and 
allowed to adhere overnight at 3 7°C with CO2 . Assays were first performed with culture 
filtrate (CF) from the different mycobacteria, which was obtained by passing culture 
broth through a Steritop™ 0.22 µm pore filter (Milipore). This culture filtrate was used 
to detect the presence of any secreted molecules. Mycolactone is both a cell associated 
and secreted molecule, so its presence can be detected in both the CF and ASLs (9). 
Therefore, it was also necessary to extract the ASLs of the different mycobacteria. 
Extracted AS Ls of my co bacteria were diluted with tissue culture medium to give a 
concentration of 20 µg/µl. Dilution of ASLs with tissue culture medium was done at a 
1 :2 ratio and serial dilutions were added to L929 cells at 1/20 of the volume. Ethanol 
(100%) as well as M u/cerans 1615 ASLs, were used as the negative and positive 
controls, respectively. At 24 h and 48 h post treatment, cells were examined 
microscopically for cell destruction and detachment. Cytopathic activity (CPA) was 
determined as the minimum amount of ASL added (µg/ml) to cause 90% cell destruction 
and lifting of cells from the monolayer. 
VI. ASL Separations of Cytopathic Mycobacteria: 
Myco bacterial cultures determined to have a cytopathic effect were grown up in 1 
liter of Middlebrook 7H9 using 850-cm2 Roller Bottles (Corning). Strains were grown 
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without shaking at 32°C and 3 7°C for CEI and TMCC, respectively. ASLs were run in 
three different solvent systems: 90:10, 93 :7, and 95 :5 (chloroform-methanol, vol/vol) to 
determine which solvent system provided the best separation {Table 1 ). Preparative TLC 
was conducted using a 7924T Chromatotron Model (Harrison Research, Palo Alto, 
California) on a 2 mm silica glass backed plate (Alltech) (Figure 4). Briefly, solvent was 
added to a separatory funnel and allowed to run through the chromatotron until 25 ml of 
solvent was collected. Next, ASLs were resuspended in 2 ml of solvent, loaded into the 
chromatotron, and 15, 5 ml fractions of solvent elute were collected. The samples were 
analyzed by TLC and visualized with eerie sulfate-ammonium molybdate in 2 M sulfuric 
acid stain. Preparative TLC was used to further separate the lipid fractions. Briefly, 
ASLs were spotted across a TLC plate and run in a chloroform-methanol solvent system. 
Lipid fractions were scrapped from the plate and the silica was collected with 25-30 ml 
Sample Recovery Tubes (Alltech). Lipids were eluted out of silica using chloroform­
methanol (90:10, vol/vol). Lipid fractions obtained by these methods were resuspended 
in 100% ethanol and tested on L929 murine fibroblasts for cytopathic activity. 
VII. Mass Spectroscopy Analysis: 
All MS analysis was performed by Richard Lee (University of Tennessee Health 
Science Center, Memphis, Tennessee) 
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Table 1 .  Solvent systems determined for chromatotron use for the Mycobacterium 
species with cytopathic lipids. 
Species/ CEI Number Solvent System Chosen 
(Chloroform-Methanol) 
M ulcerans 90: 1 0  
M scrofulaceum 93 :7 
M kansasii 95 :5 
01 -627 95:5 
0 1 -628 93 :7 
0 1 -629 93 :7 
01 -632 95 :5  
0 1 -633 93 :7 
0 1 -636 95 :5 
0 1 -664 95 :5 
0 1 -665 93 :7 
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70 cm at>ove 
bench level 
Solvent inlet 
N, 10-15 mVmin 
(250-1000 ml/min 
for initial purge) 
FIOWmeter 
Figure 4. Chromatotron Model 7924T and funnel set-up diagram. Adapted from the 
instruction manual (Harrison Research, Palo Alto, California). 
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VIII. Genomic DNA Extraction: 
Genomic DNA was extracted from the eight CEI with cytopathic ASLs (01 -627, 
01 -628, 01 -629, 01-632, 01 -633, 01 -636, 01-664, and 01-665) by using a previously 
described protocol (25). Briefly, 30 ml samples of the CEI were centrifuged at 3500 x g 
for 5 min at room temperature. The supernatant was removed and 5 ml of chloroform­
methanol (2: 1 ,  vol/vol) was added to the wet pellet and vortexed for 2 min. Mixture was 
centrifuged again at 3 500 x g and the solvents were poured off leaving the lipid lightened 
cells, and 1 ml of disruption solution ( 4 M guanidine thiocyanate, 0.025 M sodium 
citrate, pH 7.0, 0.5% (wt/vol) Sarkosyl, and 0.1 M 2-mercaptomethanol) was added and 
the mixture was vortexed for 1 min. The mixture was centrifuged at 4000 x g for 15  min 
and extracted with 1 vol phenol-chloroform-isoamyl alcohol (25:24:1, vol/vol/vol). 
Sodium acetate (3 M) at 0.1 vol and isopropanol at 1 vol were added to the aqueous 
phase. Precipitation of DNA was performed by spinning the DNA at 1200 x g for 20 min 
at 4°C. Finally DNA was washed with 70% ethanol, dried, and resuspended in water. 
All reagents used were from Sigma (St. Louis, Missouri). 
IX. Identification of Environmental Mycobacteria : 
Environmental isolates were tested for the presence of 1S2404 and 1S2606 to 
determine whether they were M ulcerans. PCR primers used for the IS elements (1S2404 
and 1S2606) in M ulcerans were used as previously described with a slight modification 
to the PCR parameters (34 ). Briefly, the primers used to amplify the 492-bp region of 
IS2404 were MUS (5'-AGC GAC CCC AGT GGA TTG GT-3') and MU6 (5'-CGG 
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TGA TCA AGC GIT CAC GA-3 '). Primers used to amplify a 332-bp region of 1S2606 
were MU7 (5 '-GGC CTG GCG GAT TGC TCA AGG-3 ') and MU8 (5'-CGT AGA TGT 
GGG CGA AAT GG-3 ') (34). Genomic DNA (1 µl) at a concentration of 50 ng/ml was 
added to 49 µ1 of the PCR amplification mixture to give a total of 50 µ1, which contained 
1 U of Taq DNA polymerase, (Promega Corporation, Madison, Wisconsin) 1 mM 
primers, 1.5 mM MgCh, and lmM dNTPs (Promega). All PCR amplifications took 
place in a thermocycler (Eppendorf Scientific Inc., Westbury, New York). The reaction 
mixtures were subjected to 5 min of denaturation at 94°C and 30 cycles of 94°C for 1 
min, 64 °C for 1 min, and 72°C for 1 min, followed by a final extension period of 72°C for 
7 min and refrigeration. 
In order to obtain taxonomic information from uncharacterized environmental 
mycobacteria, PCR of the 16S rRNA gene was performed. Genomic DNA was used for 
the PCR amplification of a region of the 16S rRNA gene, which is approximately 577-bp. 
These primers were designed from a region of the 16S rRNA gene from M tuberculosis 
and were chosen because they are constructed from highly conserved regions within M 
tuberculosis 1 6S rRNA gene. Also, within this 577-bp region are two hypervariable 
regions, A and B, which are used for species determination ( 17, 21 ). The primers used 
for this amplification, pA (5'-AGA GIT TGA TCC TGG CTC AG-3 ') and MSHE (5'­
GCG ACA AAC CAC CTA CGA G-3 ')  had been previously described (16). For the 
PCR reactions 1 µ1 of genomic DNA was added to 49 µ1 of the PCR amplification 
mixture, with the final 50 µ1 volume containing 1 U of Taq DNA polymerase (Promega). 
The PCR amplifications were again performed in a thermocycler (Eppendorf) and the 
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amplifications were performed as 4 min of denaturation at 94°C and 40 cycles of 94°C for 
1 min, 60°C for 2 min, and 72°C for 2 min, proceeded by a final extension period of 72°C 
for 7 min and refrigeration at 4 °C. 
X. PCR Product Analysis: 
The PCR products (10 µl) were visualized using a 1 % (wt/vol) agarose gel stained 
with ethidium bromide (5 µg/µl; Sigma). PCR products were then transformed using the 
TOPO TA Cloning® (Invitrogen Corporation, Carlsbad, California) kit using directions 
provided by the manufacturer. Clones containing the PCR product insert were screened 
using 5-bromo-4-chloro-3-indolyl-�-D-galactopyranoside (X-Gal)-mediated blue-white 
discrimination and ampicillin resistance. White, ampicillin-resistant transformants were 
selected and grown overnight at 37°C with shaking in Luria-Bertani (LB) broth 
containing ampicillin (50 µg/ml). Minipreps were prepared from 5 ml cultures by using 
the Wizard® Plus Minipreps DNA Purification System (Promega). The minipreps were 
digested with EcoRI (New England Biolabs, Beverly, Massachusetts) and the digestion 
products were visualized on a 1 % agarose gel ( wt/vol) stained with ethidium bromide to 
determine which clones contained the insert. Clones containing the appropriate insert 
were grown in 25 ml volumes in LB broth plus ampicillin (50 µg/ml) overnight with 
shaking at 37°C. Wizard® Plus Minipreps DNA Purification System was used again to 
isolate plasmid DNA. 
Bidirectional DNA sequences from the cloned fragments were obtained from the 
University of Tennessee Molecular Biology Sequencing Facility (Knoxville, Tennessee) 
23 
using the forward and reverse primers M13 (lnvitrogen). 
XI. Phylogenetic Analysis: 
Alignments of 16S rRNA sequences were performed using ClustalW (Megalign, 
version 5; DNAStar, Madison, Wisconsin) and compared to the 16S rRNA sequences of 
24 other Mycobacterium species as well as two Nocardia species. These 24 
Mycobacterium species were chosen based on their homology to the CEI sequences 
determined from the BLAST search. Also, representatives of fast and slow growing 
Mycobacterium species were chosen based upon their range of diversity. Nocardia 
species were chosen as the outliers due to their close relationship to the Mycobacterium 
genera, without being a member of the genera. Alignments were analyzed using the 
program Molecular Evolutionary Genetics Analysis (MEGA) package version 2.1 (22). 
MEGA was also used to determine the bootstrap values, also, which were done with 500 
permutations. A phylogenetic tree was constructed using the neighbor-joining (NJ) 
method with Jukes-Cantor distances, from the previously mentioned alignments. Partial 
16S rDNA sequences from bp-1 to approximately bp-577, differing for all the CEI, were 
used for the alignments and phylogenetic analysis of the eight environmental isolates. 
Nocardia asteroides and Nocardia farcinica were used as outgroups to root the tree. 
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3. RESULTS 
I. TLC Analysis of Mycobacteria: 
Mycolactone is a light yellow uu-active lipid with a ratio to front value (Rr) of 
0.23 in chloroform-methanol-water (90: 10: 1, vol/vol/vol) and can be seen in lane 1 of the 
TLC analyses (11) (Figure 5, 6, and 7). TLC analysis of the Trudeau Mycobacterial 
Culture Collection {TMCC) species and of the Congo environmental isolates (CEI), 
showed that whereas many species contained components which were ultraviolet (uu )­
active there was no light yellow uu-active component with a Rr similar to that of 
mycolactone run in chloroform-methanol-water (90: 10: 1, vol/vol/vol) (Data not shown). 
Since the core lactone lacks conjugated double bonds and is therefore not pigmented, it 
could not be detected by this method (24 ). TLC analysis showed that most of the 
mycobacteria tested contained many polar lipids. In fact, most of the mycobacteria tested 
contained a much greater quantity and variety of polar lipids than M ulcerans. However, 
only M ulcerans AS Ls had a lipid species indicating the presence of mycolactone 
(Figure 5, 6, and 7). 
II. Cytopathicity Assays: 
ASLs were harvested from late log phase cultures ( approximately 3 weeks for 
TMCC and 12 weeks for CEI) because this corresponded to the growth phase when 
macrolide production was at a peak in M ulcerans (24). ASLs from 66% of the 
Mycobacterium species tested, or 19 out of 29 species, were not cytopathic 
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Figure 5. Silica TLC of ASLs extracted from the slow growing TMCC tested, run in 
chloroform-methanol-water (90: 10: 1,  vol/vol/vol) and visualized by oxidative 
charring in a eerie molybdate--10% sulfuric acid stain. Strains are represented in 
lanes as follows: lane 1 ,  16 15 ;  lane 2, 706; lane 3 ,  1464; lane 4, 1467, lane 5 ,  1456; lane 
6, 1 3 1 8; lane 7, 1 3 1 9; lane 8, 1 324; lane 9, 1 203 ; lane 1 0, 1204; lane 1 1 , 1 2 14; lane 1 2, 
1 60 1 ; lane 1 3, 1 302; lane 14, 1 305; lane 1 5, 1 306; lane 1 6, 1 307; lane 1 7, 1 3 1 2; lane 1 8, 
1 3 14; lane 1 9, 1 3 1 5 ; lane 20, 1 3 1 6; lane 2 1 ,  1 320; lane 22, 1 32 1 ;  lane 23, 1 323 ; lane 24, 
148 1 ;  lane 25, 1 541 . "*" indicates mycolactone A/B. 
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Figure 6. TLC of ASLs extracted from the slow growing CEI, run in chloroform­
methanol-water (90:10: 1, vol/vol/vol) and visualized by oxidative charring in a eerie 
molybdate-10% sulfuric acid stain. Strains are represented in lanes as follows: lane 
1 ,  161 5; lane 2, 01 -626; lane 3, 01-627; lane 4, 01 -628; lane 5, 01 -629; lane 6, 01 -630; 
lane 7, 01 -631 ; lane 8, 01 -632; lane 9, 01 -633; lane 10, 01 -634; lane 1 1 ,  01 -635; lane 12, 
01 -636; lane 1 3 , 0 1 -664; lane 14, 01 -665; lane 1 5, 01 -666; lane 1 6, 01 -667; lane 1 7, 0 1 -
668. "*" indicates mycolactone A/B. 
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Figure 7. TLC of ASLs extracted from fast growing TMCC, run in chloroform­
methanol-water (90: 10: 1, vol/vol/vol) and visualized by oxidative charring in a eerie 
molybdate-10% sulfuric acid stain. Strains are represented in lanes as follows: lane 
1, 1615; lane 2, 1524; lane 3, 1543; lane 4, 1529; lane 5, 1530; lane 6 1516; lane 7, 1515. 
"*" indicates mycolactone A/B. 
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on L929 cells. None of the fast growing Mycobacterium species tested contained 
cytopathic lipids {Table 2). However, two slow growing, human pathogens, M 
scrofulaceum and M kansasii, did contain cytopathic ASLs. In addition it was surprising 
to find that, 8 out of the 16 CEI species tested (01-627, 01-628, 01-629, 01-632, 01-633, 
01-636, 01-664, and 01-665) contained cytopathic ASLs {Table 3). However the 
cytopathic activity (CPA) of all of these lipids found differed greatly both in potency and 
cytopathic phenotype from that of mycolactone. Firstly, none of the lipids tested 
approached the potency of mycolactone. For example, cytotoxic ASLs from 
Mycobacterium species other than M ulcerans have CPA values that are 105-107 higher 
than ASLs from 1615 M ulcerans. Whereas 1615 M ulcerans ASLs were cytopathic at 
2.12 ng/ml, the cytopathic ASLs from other isolates exhibited a cytopathic activity at 
concentrations ranging from 2.00 x 104-3 .30 x 102 µg/ml, values which require much 
more ASL to be added to see cytopathic activity. Therefore, 1615 M ulcerans ASLs are 
more than 100,000 fold more active than any other cytopathic lipid {Table 3). Potency 
alone can not rule out the presence of mycolactone. Many more lipid fractions were 
isolated from some of the Mycobacterium species therefore the possibility exists that the 
molecule responsible for activity could be present in small amounts. 
However the specific cytopathic effect produced by other mycobacterial ASLs 
differed both in terms of kinetics as well as in the morphological phenotype observed 
from that of mycolactone. Mycolactone mediated cytotoxicity developed slowly and cell 
rounding was not prominent for 18-24 hours. In contrast cytopathicity observed for 
ASLs from non-M ulcerans bacteria developed much more rapidly and was obvious by 
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Table 2. Fast growing Mycobacterium species used in this study and the results of 
the ASLa cytopathicity assays for the fast growing mycobacteria. 
TMC6 Number and Species Source CPAc of ASL 
(pe/ml) 
1 6 1 5  M ulcerans (ATCC 35840) TMCC 0.0021 
1 524 M chelonae (ATCC 35749) TMCC -
1 543 M chelonae (ATCC 19977) TMCC -
l 529 M fortuitum (A TCC 684 1) TMCC -
1 530 M fortuitum (ATCC 35754) TMCC -
1 5 1 6  M phlei (ATCC 35784) TMCC -
1 5 1 5 M smegmatis (ATCC 35797) TMCC -
a ASLs of a chloroform-methanol (2: 1 ,  vol/vol) extract 
b TMC, Trudeau Mycobacterial Culture; TMCC, Trudeau Mycobacterial Culture 
Collection. 
c CPA is defined as the minimal amount of AS Ls added (µg/ml) to cause 90% cell 
destruction and detachment. 
d "-", means no cytopathic effect seen at < 20 µg/µl. 
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Table 3. Slow growing Mycobacterium species used in this study and the results of 
the ASL a cytopathicity assays for the slow growing my co bacteria. 
TMC" Number and Species Source CPA'-' of ASLs 
Environmental Strain Number (µg/ml) 
1615  M ulcerans (ATCC 35840) TMCC 0.002 1 
706 M avium (ATCC 35714) TMCC _d 
' 1464 M intrace/lulare (ATCC 35768) TMCC -
1467 M intrace/lulare (ATCC 35770) TMCC -
1456 M gastri (ATCC 15754) TMCC -
1 3 1 8  M gordonae (ATCC 35756) TMCC -
1 3 19 M gordonae (ATCC 35757) TMCC -
1 324 M gordonae (ATCC 14470) TMCC -
1203 M kansasii (ATCC 35776) TMCC 10000 
1 204 M kansasii (ATCC 12478) TMCC 1250 
1214  M kansasii (ATCC 35777) TMCC 5000 
1 601 M microti (ATCC 35781 )  TMCC -
1 302 M scrofulaceum (ATCC 35785) TMCC 10000 
1 305 M scrofulaceum (ATCC 35786) TMCC -
1 306 M scrofulaceum (ATCC 35787) TMCC I 10000 
1 307 M scrofulaceum (ATCC 35788) TMCC 10000 
1 3 12  M scrofulaceum (ATCC 35790) TMCC 20000 
1 3 14 M scrofu/aceum (ATCC 35791) TMCC 10000 
1 3 1 5  M scrofulaceum (ATCC 35792) TMCC 20000 
: 1 3 1 6  M scrofu/aceum (ATCC 35793) TMCC 20000 
1 320 M scrofulaceum (ATCC 35794) TMCC -
I 1 321  M scrofulaceum (ATCC 35795) TMCC -
1 323 M scrofulaceum (ATCC 19981 )  TMCC -
, 148 1  M nonchromogenicium (ATCC 19530) TMCC -
1 54 1  M jlavescens (ATCC 14474) TMCC -
01-626 CEI -
01-627 CEI 2500 
I 01 -628 CEI 2500 
0 1-629 CEI 10000 
01-630 CEI -
01-63 1 CEI -
I 01-632 CEI 1600 
I 01-633 CEI 10000 01-634 CEI -
01-635 CEI -
01-636 CEI 2500 
0 1-664 CEI 2500 
0 1-665 CEI 330 
0 1-666 CEI -
0 1-667 CEI -
01-668 CEI -
a ASLs of a chloroform-methanol (2: 1 ,  voVvol) extract 
b TMC, Trudeau Mycobacterial Culture; TMCC, Trudeau Mycobacterial Culture 
Collection; CEI, Congo Environmental Isolate obtained from Francoise Portaels. 
i 
! 
I 
c CPA is defined as the minimal amount of ASLs added (µg/ml) to cause 90% cell 
destruction and detachment. 
d "-", means no cytopathic effect seen at < 20 µg/µl. 
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4-6 hours. Differences in cell morphology also clearly distinguished ASLs from M 
ulcerans from other cytopathic lipids. Whereas mycolactone treated cells were 
characterized by eccentric nuclei and clear cytoplasm (Figure 9), vacuolization was the 
prominent feature produced by ASLs from non-M ulcerans isolates (Figure 10 and 
Figure 1 1  ). Phenotypically, undisturbed L929 fibroblasts appeared as rhomboid cells 
lining the bottom of the well which formed a confluent monolayer by 48 h (Figure 8). 
Mycolactone had a readily identifiable and specific effect on L929 cells, characterized by 
cell rounding within 24 h, inhibition of cell growth, and detachment of the mono layer 
within 48 h (9) (Figure 9). None of the other lipids tested exhibited this phenotype. 
Most of the cytopathic ASLs shared a similar phenotype characterized by vacuole-like 
structures, which filled the cytoplasm of the cell. Two forms of vacuolization were 
detected. In one case extensive vacuolization occurred. This phenotype was seen with 
ASLs from M scrofulaceum species, M kansasii species, CEI 01 -627, CEI 01 -633, and 
CEI 0 1-636. These lipid samples produced many distinct vacuoles which filled the 
cytoplasm of the cell. Vacuoles could be detected as early as 6 h although maximum 
vacuolization did not occur until 24 h (Figure 10). A second phenotype, typified by CEI 
01 -628, CEI 01 -629, CEI 01 -632, CEI 01 -664, and CEI 01 -665, was characterized by 
simultaneous vacuolization and cell rounding by 4 h with the majority of cells being 
rounded and filled with vacuoles by 24 h. Eventually, cell lysis occurred and the 
vacuoles were seen free in the tissue culture media (Figure 1 1  ). Vacuolization does not 
occur in cells treated with M ulcerans ASLs or purified mycolactone or mycolactone 
core (9, 10, 24). These results show that neither mycolactone nor the core mycolactone 
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Figure 8. Undisturbed L929 fibroblasts. Picture was taken at 48 h and 200 x 
magnification. 
Figure 9. 1615 M. ulcerans ASLs added to L929 fibroblasts at a concentration of 
2.12 ng/ml. Picture was taken at 48 h and 200 x magnification. 
33 
Figure 10. First typical phenotype of extensive vacuolization. Vacuolization seen 
here is with CEI 0 1-629 on L929 fibroblasts at 48 h and 200 x magnification. 
Figure 11 .  Second phenotype of simultaneous rounding and vacuolization. 
Vacuolization seen here with CEI 01-632 on L929 fibroblasts at 48 h and 200 x 
magnification. 
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lipid were present in any of the 46 Mycobacterium isolates tested. 
III. Culture Filtrate Analysis : 
George et al. have previously shown that mycolactone is secreted into the culture 
filtrate (CF) of the bacteria culture, and therefore, the CF of 1615 M ulcerans exhibits a 
cytopathic effect on L929 cells with characteristic cell rounding and detachment (9). 
The CF of all other Mycobacterium species in this study were tested for CPA on L929 
fibroblasts and none were cytopathic to L929 cells, even the species with slight 
cytopathic activity within their ASLs (Data not shown). However, ASLs from the CF of 
the non-M ulcerans species of Mycobacterium were not extracted from the CF due to the 
lack of activity initially seen with their CFs. Most likely the cytopathic lipids are not 
secreted into the CF like mycolactone is, or these lipids are not potent enough to be 
detected. Also, the responsible lipid may be in the CF in quantities too small to be 
detected. In summary, the cytopathicity assays with AS Ls and CF further suggest that 
out of the mycobacteria tested only M ulcerans produces mycolactone. 
IV. Purification of Cytopathic Lipids : 
Cultures of Mycobacterium species which contained cytopathic ASLs were 
expanded to one liter to obtain sufficient lipids for analysis of individual lipid species. 
Unfortunately, we were unable to assign cytopathic activity to specific lipids in most 
cases due to the poor growth of many of the species and the small amounts of lipids 
produced. Many environmental mycobacteria grow very slowly and only at low 
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temperatures. In some cases 6 months of growth was required before cultures reached 
late log phase. 
A specific cytopathic lipid was purified from CEI 0 1 -628 ASLs by chromatotron 
separation (Figure 12). The cytopathic fraction was a lipid with a Rr value of 0. 14  in a 
solvent system of chloroform-methanol (93 :7, vol/vol) and a CPA of 2.5 x 1 03 µg/ml, 
which is the same CPA seen with whole ASLs of CEI 0 1 -628 . A lower CPA value than 
whole ASLs would be indicative of a pure lipid species, and this was not seen here. 
However, the cytopathicity phenotype on L929 cells of CEI 01 -628 cytopathic lipid 
fraction matched the phenotype of whole AS Ls (Data not shown). 
The cytopathic fraction of CEI O 1 -628 was less polar than mycolactone, which 
has an Rr of 0.08 when run in chloroform-methanol (93 :7, vol/vol). Also, CEI 0 1 -628 
cytopathic fraction lacked the potency of mycolactone (2. 1 2  ng/ml), and specific 
phenotype seen with mycolactone as well as uu activity. Mass spectroscopy (MS) 
analysis was performed on this lipid component of CEI O 1 -628 to further distinguish it 
from mycolactone and the core lactone (Figure 1 3  ). Mycolactone produces a molecular 
ion at mlz 765 .5 [M+Nat whereas the core lactone is detected as a peak at m/z 447 
[M+Nat (10) (24) (Figure 14). Analysis of the cytopathic fraction of 01 -628 shows that 
there is no peak at mlz 765 .5 or at mlz 447 [M+Nat. Instead a major peak for CEI 0 1 -
628 was seen at mlz 279. 1 [M+Nat as well as several minor peaks. Therefore, it i s  quite 
obvious that this cytopathic fraction in CEI O 1 -628 is not mycolactone nor is the 
cytopathic fraction the core lactone. From the MS, TLC, and cell assay data we were 
able to confirm that the cytopathic lipid of CEI 01 -628 was in fact not mycolactone or the 
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Figure 12. TLC analysis of CEI 01-628 ASLs from chromatotron spearation. Lane 
1 ,  0 1 -628 whole AS Ls; lane 2, 0 1 -628 ASL cytopathic fraction. "*", cytopathic lipid 
fraction. Rr value of cytopathic fraction is 0. 14. TLC was run in chloroform-methanol 
(93 :7, vol/vol) as the solvent system. 
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Figure 13. Mass Spectroscopy analysis of CEI 01-628 cytopathic fraction. The 
major species here occurs at a peak of mlz 279.1 [M+Nat. 
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Figure 14. Mass Spectroscopy analysis of 1615 M. ulcerans ASLs. "*" indicates 
mycolactone, the most abundant species present. "**" indicates the core lactone. 
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core lactone. Furthermore, it can be concluded from the TLC data and the cell assay data 
that these other species of Mycobacterium that contain cytopathic lipids most likely do 
not contain mycolactone or the core lactone. More specifically, CEI 01-628 cytopathic 
fraction causes a vacuolization phenotype on L929 fibroblasts. This fraction was 
definitively identified as not mycolactone or the core lactone. Therefore, it can be 
concluded that because the other non-M ulcerans species exhibit vacuolization too, they 
also do not contain mycolactone or the core lactone. 
V. Identification of the 8 CEI with Cytopathic Lipids : 
The CEI are slow growing, environmental mycobacteria isolated from water in a 
geographic area where M ulcerans is endemic. All 16 CEI were isolated by Francoise 
Portaels (Institute of Tropical Medicine, Antwerp, Belguim) in the Democratic Republic 
of Congo, in the late 1 970s. These strains were isolated from the Lower-Congo region, 
between Kinshasa and Moanda. These Mycobacterium isolates were determined to be 
slow growing mycobacteria with an optimal growth temperature of 33°C and sensitivity 
to dapsone. At the time of isolation, they were tested against all presently known species 
of Mycobacterium and did not match any known species in the late 1970s (28). 
Furthermore, tools for determining taxonomic relationships of new mycobacteria isolates 
have been more developed since then. In addition, the IS element based PCR diagnostic 
tool for M ulcerans identification had not been developed when these species were 
isolated (34) .  Due to the fact the CEI were isolated in areas endemic to M ulcerans 
infection, further characterization of these species was necessary. In addition it was 
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important to show that none of these CEI were M ulcerans. The growth and colonial 
morphology of the CEI vary considerably; most isolates do not look phenotypically like 
M ulcerans (Table 4). Also, these CEI were determined to have no growth at 37°C, but 
we have determined that poor growth occurs at 37°C (34) (Table 4). 
In addition M ulcerans contains two insertion sequences (IS2404 and IS2606) 
that are almost entirely unique to M ulcerans (34). PCR detection of these two IS 
elements has become the gold standard used for diagnosis and identification of M 
ulcerans. The possibility existed that some of these environmental isolates might 
represent M ulcerans strains that do not have genes for mycolactone. Therefore, PCR 
was used to determine whether IS2404 or IS2606 were present in the 8 CEI with 
cytopathic lipids. Furthermore, because CEI species were isolated in aquatic habitats in 
areas endemic to M ulcerans, we wanted to show that these species did not contain these 
IS elements found in M ulcerans as this finding would strengthen the diagnostic validity 
of the PCR test on M ulcerans (30). PCR results show that genomic DNA from M 
ulcerans 1615 contains both the 492-bp fragment of IS2404 and the 332-bp fragment of 
IS2606. However, none of the CEI with cytopathic lipids contained either of these IS 
elements (Figure 15). Also, the remaining CEI (01-626, 01-630, 01-631, 01-634, 01-
635, 01-666, 01-667, and 01-668) were tested for IS2404 and IS2606 by PCR. These 
species were also negative for both of these IS elements (Data not shown). 
In order to further characterize the environmental isolates, partial sequencing of 
the 16S rRNA gene was done to determine the relationship of the uncharacterized CEI to 
other fast and slow growing species of Mycobacterium. First PCR was performed using 
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Table 4. Characterizations of uncharacterized slow growing mycobacteria from 
aquatic sources from the Democratic Republic of Congo. 
Strain N um her Growth Morphologya/ Pigmentaion Growth 
Tern peratures 
32°c 31°c 
16 15  M ulcerans Smooth and Rough/Nonphotochromogenicc +d -
01-626 Rough/ Nonphotochromogenic + +/-
01-627 Smooth/ Scotochromogenic + + 
01-628 Rough/ Nonphotochromogenic + +/-
01-629 Rough/ Photochromogenic + +/-
0 1-630 Smooth and Rough/ Scotochromogenic + +/-
0 1-63 1 Rough/ Scotochromogenic + +/-
0 1 -632 Rough/ Nonphotochromogenic + +/-
01-633 Smooth and Rough/ Nonphotochromogenic + +/-
01-634 Smooth/ Scotochromogenic + +/-
01-635 Smooth/ Scotochromogenic + +/-
01-636 Smooth/ Scotochromogenic + + 
0 1-664 Rough/ N onphotochromogenic + +/-
01 -665 Rough/ Scotochromagenic + +/-
0 1-666 Smooth/ Nonphotochromogenic + +/-
01-667 Smooth/ Scotochromogenic + +/-
01-668 Smooth and Rough/ Scotochromogenic + +/-
a Growth morphology as plated on Middelbrook 7H10 media. 
b Cytopathicity on L929 fibroblasts. 
Cytopathicity" 
Yes 
No 
Yes 
Yes 
Yes 
No 
No 
Yes 
Yes 
No 
No 
Yes 
Yes 
Yes 
No 
No 
No 
c Nonphotochromogenic lacks the production of pigment with or without light present; 
Scotochromogenic produces pigment with or without light present; Photochromogenic 
produces pigment only after exposure to light. All pigment definitions taken from Kent 
et al. (20). 
d "+" indicates growth; "-" indicates no growth; "+/-" indicates weak growth. 
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492-bp 
332-bp 
M 1 2 3 4 5 6 7 8 9 1 0  
Figure 15. PCR analysis of 8 CEI with cytopathic lipids for 1S2404 and 1S2606. 
Lane M, 1-Kb ladder (Invitrogen); lane 1, M ulcerans; lane 2, 01-627; lane 3, 01-628; 
lane 4, 01-629; lane 5, 01-632; lane 6, 01-633; lane 7, 01-636; lane 8, 01-664; lane 9, 01-
665; lane 10, water. The 492-bp fragment represents 1S2404 and the 332-bp fragment 
represents 1S2606. 
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genomic DNA of these 8 CEI with cytopathic lipids, using primers based on hp 1 -577 of 
the M tuberculosis 16S rRNA gene (16S rDNA) as previously described (16). The 
primers used to amplify 16S rDNA in this study, pA and MSHE, were chosen because of 
the length of the fragment amplified and because they sequence two hypervariable 
regions in Mycobacterium species16S rRNA gene, A and B. Hypervariable region A is 
between hp 129-276 and hypervariable region B in between hp 430-495 using 
Escherichia coli 16S rDNA as a reference point for nucleotides. Both of these variable 
regions are useful in determining within species variations (2 1 ). All 8 of the CEI with 
cytopathic lipids as well as 1615 M ulcerans were positive for the 16S rRNA fragment, 
which was amplified by primers designed from a 577-bp region of M tuberculosis, 
whereas a water control was negative (Figure 16). The results of the PCR test further 
confirmed that these CEI were in fact species of Mycobacterium, and these PCR products 
were cloned and used for sequencing. The 16S rDNA obtained from sequencing was 
approximately 577-bp and contained both variable regions, A and B (Figure 17, 1 8, 19, 
20, 21 ,  22, 23 and 24). The 8 different CEI 16S rDNA were all sequenced twice to 
determine accuracy. BLAST analysis showed that these sequences were unique 
mycobacterial sequences although they were closely related to 16S rRNA sequence for 
Mycobacterium scrofulaceum, Mycobacterium celatum, or Mycobacterium coo/di. CEI 
01 -627 and CEI 01 -636 16S rDNA sequences were 99 % (547 identical bases out of 552 
for both CEI) homologous to M scrofulaceum and CEI 0 1 -629 was 96% ( 540 bases 
identical out of 558) homologous to M scrofulaceum, according to the BLAST analysis. 
CEI 01 -664 was 97% (534/549) homologous to M celatum, while 01 -632 and 0 1 -628 
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M 1 2 3 4 5 6 7 8 9 10  
577-bp .. 
Figure 16. PCR analysis of 8 CEI with cytopathic lipids for the partial 16S rRNA 
fragment (577-bp). Lane M, 1 -Kb ladder (lnvitrogen); lane 1 ,  M ulcerans; lane 2, 0 1 -
627; lane 3 ,  0 1 -628; lane 4, 01 -629; lane 5 ,  0 1 -632; lane 6, 0 1 -633;  lane 7, 01 -636; lane 
8, 01 -664; lane 9, 01 -665; lane 1 0, water. 
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AGA GTT TGA TCC TGG CTC AGG ACG AAC GCT GGC GGC GTG CTT AAC 45 
ACA TGC AAG TCG AAC GGA AAG GCC TCT TCG GAG GTA CTC GAG TGG 90 
CGA ACG GGT GAG TAA CAC GTG GGC AAT CTG CCC TGC ACT TCG GGA 135 
TAA GCC TGG GAA ACT GGG TCT AAT ACC GAA TAG GAC CAC TTG GCG 180 
CAT GCC TTG TGG TGG AAA GCT TTT GCG GTG TGG GAT GGG CCC GCG 225 
GCC TAT CAG CTT GTT GGT GGG GTG ATG GCC TAC CAA GGC GAC GAC 270 
GGG TAG CCG GCC TGA GAG GGT GTC CGG CCA CAC TGG GAC TGA GAT 315 
ACG GCC CAG ACT CCT ACG GGA GGC AGC AGT GGG GAA TAT TGC ACA 360 
ATG GGC GCA AGC CTG ATG CAG CGA CGC CGC GTG GGG GAT GAC GGC 405 
CTT CGG GTT GTA AAC CTC TTT CAC CAT CGA CGA AGG CTC ACT TTG 450 
TGA GTT GAC GGT AGG TGG AGA AGA AGC ACC GGC CAA CTA CGT GCC 4 95 
AGC AGC CGC GGT AAT ACG TAG GGT GCG AGC GTT GTC CGG AAT TAC 540 
TGG GCG TAA AGA GCT CGT AGG TGG TTT GTC GC 572 
Figure 17. Partial 16S rDNA sequence of CEI 01-627. Nucleotide numbers are 
located to the right of the sequence and are in bold. 
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AGA GTT TGA TCC TGG CTC AGG ACG AAC GCT GGC GGC GTG CTT AAC 45 
ACA TGC AAG TCG AAC GGA AAG GCC CTG CTT GCA GGG TGC TCG AGT 90 
GGC GAA CGG GTG AGT AAC ACG TGG GTG ATC TGC CCT GCA CTT CGG 135 
GAT AAG CTT GGG AAA CTG GGT CTA ATA CCG GAT AGG ACC ACA TGC 180 
TGC ATG GTG TGT GGT GGA AAG CTT TTT GCG GTG TGG GAT GGG CCC 225 
GCG GCC TAT CAG CTT GTT GGT GGG GTG ATG GCC TAC CAA GGC GAC 270 
GAC GGG TAG CCG GCC TGA GAG GGT GTC CGG CCA CAC TGG GAC TGA 315 
GAT ACG GCC CAG ACT CCT ACG GGA GGC AGC AGT GGG GAA TAT TGC 360 
ACA ATG GGC GCA AGC CTG ATG CAG CGA CGC CGC GTG GGG GAT GAC 405 
GGC CTT CGG GTT GTA AAC CTC TTT CAC CAT CGA CGA AGG CCC GCG 450 
TTT GTG GGT TGA CGG TAG GTG GAG AAG AAG CAC CGG CCA ACT ACG 495 
TGC CAG CAG CCG CGG TAA TAC GTA GGG TGC GAG CGT TGT CCG GAA 540 
TTA CTG GGC GTA AAG AGC TCG TAG GTG GTT TGT CGC 57 6 
Figure 18. Partial 16S rDNA sequence of CEI 01-628. Nucleotide numbers are 
located to the right of the sequence and are in bold. 
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AGA GTT TGA TCC TGG CTC AGG ACG AAC GCT GGC GGC GTG CTT AAC 45 
ACA TGC AAG TCG AAC GGA AAG GCC CCT TTC GGG GGG TAC TCG AGT 90 
GGC GAA CGG GTG AGT AAC ACG TGG GTG ATC TGC CCT GCA CTT CGG 135 
GAT AAG CTT GGG AAA CTG GGT CTA ATA CCG GAT AGG ACT CTT GGC 180 
TGC ATG GTT GAG AGT GGA AAG CTT TTG CGG TGT GGG ATG GGC CCG 225 
CGG CCT ATC AGC TTG TTG GTG GGG TGA TGG CCT ACC AAG GCG ACG 270 
ACG GGT AGC CGG CCT GAG AGG , GTG TCC GGC CAC ACT GGG ACT GAG 315 
ATA CGG CCC AGA CTC CTA CGG GAG GCA GCA GTG GGG AAT ATT GCA 360 
CAA TGG GCG CAA GCC TGA TGC AGC GAC GCC GCG TGG GGG ATG ACG 405 
GCC TTC GGG TTG TAA ACC TCT TTC ACC ATC GAC GAA GGC CCG CTT 450 
TTG GTG GGT TGA CGG TAG GTG GAG AAG AAG CAC CGG CCA ACT ACG 4 95 
TGC CAG CAG CCG CGG TAA TAC GTA GGG TGC GAG CGT TGT CCG GAA 540 
TTA CTG GGC GTA AAG AGC TCG TAG GTG GTT TGT CGC 576 
Figure 19. Partial 16S rDNA sequence of CEI 01-629. Nucleotide numbers are 
located to the right of the sequence and are in bold. 
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AGA GTT TGA TCC TGG CTC AGG ACG AAC GCT GGC GGC GTG CTT AAC 45 
ACA TGC AAG TCG AAC GGA AAG GCC CCT TTC GGG GGG TAC TCG AGT 90 
GGC GAA CGG GTG AGT AAC ACA TGG GTG ATC TGC CCT GCA CTT CGG 135 
GAT AAG CTT GGG AAA CTG GGT CTA ATA CCG GAT AGG ACC ACG GCC 180 
TGC ATG GGT TGT GGT GGA AAG CTT TTG CGG TGT GGG ATG GGC CCG 225 
CGG CCT ATC AGA TTG TTG GTG GGG TGA TGG CCT ACC AAG GCG ACG 270 
ACG GGT AGC CGG CCT GAG AGG GTG TCC GGC CAC ACT GGG ACT GAG 315 
ATA CGG CCC AGA CTC CTA CGG GAG GCA GCA GTG GGG AAT ATT GCA 360 
CAA TGG GCG CAA GCC TGA TGC AGC GAC GCC GCG TGG GGG ATG ACG 405 
GCC TTC GGG TTG TAA ACC TCT TTC ACC ATC GAC GAA GGC CCG CTT 450 
TTG GTG GGT TGA CGG TAG GTG GAG AAG AAG CAC CGG CCA ACT ACG 4 95 
TGC CAG CAG CCG CGG TAA TAC GTA GGG TGC GAG CGT TGT CCG GAA 540 
TTA CTG GGC GTA AAG AGC TCG TAG GTG GTT TGT CGC 576 
Figure 20. Partial 16S rDNA sequence of CEI 01-632. Nucleotide numbers are 
located to the right of the sequence and are in bold. 
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AGA GTT TGA TCC TGG CTC AGG ACG AAC GCT GGC GGC GTG CTT AAC 45 
ACA TGC AAG TCG AAC GGA AAG GCC CTT TCG GGG GTA CTC GAG TGG 90 
CGA ACG GGT GAG TAA CAC GTG GGT GAT CTG CCC TGC ACT TCG GGA 135 
TAA GCT TGG GAA ACT GGG TCT AAT ACC GGA TAG GAC TAC GAG TCG 180 
CAT GGC TTG TGG TGG AAA GCT TTT GCG GTG TGG GAT GGG CCC GCG 225 
GCC TAT CAG CTT GTT GGT GGG GTG ATG GCC TAC CAA GGC GAC GAC 270 
GGG TAG CCG GCC TGA GAG GGT GTC CGG CCA CAC TGG GAC TGA GAT 315 
ACG GCC CAG ACT CCT ACG GGA GGC AGC AGT GGG GAA TAT TGC ACA 360 
ATG GGC GCA AGC CTG ATG CAG CGA CGC CGC GTG GGG GAT GAC GGC 405 
CTT CGG GTT GTA AAC CTC TTT CAC CAT CGG CGA AGC CAG GGA CTT 450 
TTG TCT TCT GGT GAC GGT AGG TGG AGA AGA AGC ACC GGC CAA CTA 495 
CGT GCC AGC AGC CGC GGT AAT ACG TAG GGT GCG AGC GTT GTC CGG 540 
AAT TAC TGG GCG TAA AGA GCT CGT AGG TGG TTT GTC GC 578 
Figure 21. Partial 16S rDNA sequence of CEI 01-633. Nucleotide numbers are 
located to the right of the sequence and are in bold. 
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AGA GTT TGA TCC TGG CTC AGG ACG AAC GCT GGC GGC GTG CTT AAC 45 
ACA TGC AAG TCG AAC GGA AAG GCC TCT TCG GAG GTA CTC GAG TGG 90 
CGA ACG GGT GAG TAA CAC GTG GGC AAT CTG CCC TGC ACT TCG GGA 135 
TAA GCC TGG GAA ACT GGG TCT AAT ACC GAA TAG GAC CAC TTG GCG 180 
CAT GCC TTG TGG TGG AAA GCT TTT GCG GTG TGG GAT GGG CCC GCG 225 
GCC TAT CAG CTT GTT GGT GGG GTG ATG GCC TAC CAA GGC GAC GAC 270 
GGG TAG CCG GCC TGA GAG GGT GTC CGG CCA CAC TGG GAC TGA GAT 315 
ACG GCC CAG ACT CCT ACG GGA GGC AGC AGT GGG GAA TAT TGC ACA 360 
ATG GGC GCA AGC CTG ATG CAG CGA CGC CGC GTG GGG GAT GAC GGC 405 
CTT CGG GTT GTA AAC CTC TTT CAC CAT CGA CGA AGG CTC ACT TTG 450 
TGA GTT GAC GGT AGG TGG AGA AGA AGC ACC GGC CAA CTA CGT GCC 4 95 
AGC AGC CGC GGT AAT ACG TAG GGT GCG AGC GTT GTC CGG AAT TAC 540 
TGG GCG TAA AGA GCT CGT AGG TGG TTT GTC GC 572 
Figure 22. Partial 16S rDNA sequence of CEI 01-636. Nucleotide numbers are 
located to the right of the sequence and are in bold. 
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GGA CGA ACG CTG GCG GCG TGC TTA ACA CAT GCA AGT CGA ACG GAA 45 
AGG CCC CTT TCG GGG GGT ACT CGA GTG GCG AAC GGG TGA GTA ACA 90 
CGT GGG TGA TCT GCC CTG CAC TTC GGG ATA AGC TTG GGA AAC TGG 135 
GTC TAA TAC CGG ATA GGA CCA TGC CAT GCA TGT GGT GTG GTG GAA 180 
AGC TTT TGC GGT GTG GGA TGG GCC CGC GGC CTA TCA GCT TGT TGG 225 
TGG GGT GAT GGC CTA CCA AGG CGA CGA CGG GTA GCC GGC CTG AGA 270 
GGG TGT CCG GCC ACA CTG GGA CTG AGA TAC GGC CCA GAC TCC TAC 315 
GGG AGG CAG CAG TGG GGA ATA TTG CAC AAT GGG CGC AAG CCT GAT 360 
GCA GCG ACG CCG CGT GGG GGA TGA CGG CCT TCG GGT TGT AAA CCT 405 
CTT TCA CCA TCG ACG AAG GCC CGC TCT GCG GGT TGA CGG TAG GTG 450 
GAG AAG AAG CAC CGG CCA ACT ACG TGC CAG CAG CCG CGG TAA TAC 495 
GTA GGG TGC GAG CGT TGT CCG GAA TTA CTG GGC GTA AAG AGC TCG 540 
TAG GTG GTT TGT CGC 565 
Figure 23. Partial 16S rDNA sequence of CEI 01-664. Nucleotide numbers are 
located to the right of the sequence and are in bold. 
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AGA GTT TGA TCC TGG CTC AGG ACG AAC GCT GGC GGC GTG CTT AAC 45 
ACA TGC AAG TCG AAC GGA AAG GTC TCT TCG GAG ATA CTC GAG TGG 90 
CGA ACG GGT GAG TAA CAC GTG GGT GAT CTG CCC TGC ACT TCG GGA 135 
TAA GCT TGG GAA ACT GGG TCT AAT ACC GGA TAT GAT CAC ACG CTT 180 
CAT GGT GTG TGG TGG AAA GCT TTT GCG GTG TGG GAT GGG CCC GCG 225 
GCC TAT CAG CTT GTT GGT GGG GTA ATG GCC TAC CAA GGC GAC GAC 270 
GGG TAG CCG GCC TGA GAG GGT GTC CGG CCA CAC TGG GAC TGA GAT 315 
ACG GCC CAG ACT CCT ACG GGA GGC AGC AGT GGG GAA TAT TGC ACA 360 
ATG GGC GCA AGC CTG ATG CAG CGA CGC CGC GTG GGG GAT GAC GGC 405 
CTT CGG GTT GTA AAC CTC TTT CAC CAT CGG CGA AGC CGG ATG CTT 450 
TTG TGT CTG GTG ACG GTA GGT GGA GAA GAA GCA CCG GCC AAC TAC 495 
GTG CCA GCA GCC GCG GTA ATA CGT AGG GTG CGA GCG TTG TCC GGA 540 
ATT ACT GGG CGT AAA GAG CTC GTA GGT GGT TTG TCG C 577 
Figure 24. Partial 16S rDNA sequence of CEI 01-665. Nucleotide numbers are 
located to the right of the sequence and are in bold. 
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were 96% (550/572 and 551 /573, respectively) homologous. Finally, 01 -633 was 97% 
(546/558) homologous and 01 -665 was 96% (538/557) homologous to M coo/di. All 
BLAST homologies had an expect value (E value) of 0.0, showing that these results were 
not due to chance. The results from the BLAST searches further indicated that these 8 
CEI were not M ulcerans. Furthermore, it confirmed that each of these 8 CEI were new 
species of Mycobacterium. 
Alignments containing the partial sequence of the 8 CEI with cytopathic lipids 
were performed using 24 other Mycobacterium species ( accession numbers are listed in 
Table 5) in order to place the new isolates in a taxonomic tree. These alignments were 
performed using ClustalW in the program Megalign (DNAStar). Variable regions within 
the 16S rRNA gene were important determinants of species differentiation (32). 
Hypervariable region A ranged from bp-129 through bp-276 and the CEI showed a 
significant amount of differentiation from known Mycobacterium species (Figure 25). 
Likewise, hypervariable region B (bp 430-495) also showed a significant amount of 
variation between the 8 CEI with cytopathic lipids as well as known Mycobacterium 
species (2 1 )  (Figure 26). These 1 6S rRNA hypervariable regions were very different for 
the CEI when compared to other Mycobacterium species and were a good indicator that 
the CEI were new species. A phylogenetic tree was constructed from these species with 
the MEGA program using the NJ method with Jukes-Cantor distances and Nocardia 
asteroides and Nocardia farcinica were used as outgroups to root the tree. Bootstrap 
values were calculated with 500 permutations, and those bootstrap values that were 
greater than 50, out of a total value of 100, were indicated with an asterisk (Figure 27). 
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Table 5. Accession numbers for Mycobacterium species used in the alignments for 
this study. Accession numbers for the different species of Mycobacterium were obtained 
from the GenBank Database. 
Species Accession Number 
M avium AF306455 
M avium subsp. paratuberculosis X52934 
M bovis X55589 
M celatum L08 1 69 
M chelonae X5292 1 
M cookii AF480598 
M jlavescens X52932 
M gastri X52919  
M gordonae AJ536042 
M intracellulare AJ536036 
M kansasii AJ536035 
M leprae X5399 
M marinum AJ536032 
M nonchromogenicum X52928 
M peregrinum AF130308 
M phlei AF480603 
M scrofulaceum AJ536034 
M septicum AFl 1 1 809 
M simiae X5293 1 
M smegmatis AJ 13 176 1  
M terrae X52925 
M tuberculosis AJ1 3 1 120 
M ulcerans X58954 
M xenopi AJ536033 
N. asteroides X84850 
N. farcinica X9104 1  
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129  
M. tuberculosis TGATCTGCCCTGCACTTC-GGGATAAGCCTGGGAAACTGGGTCTAATACCGGATAGG-ACCACGGG-CTGCATG 
M. ul cerans C • • • • • • • • • • • • • • • • •  - • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •  - • • • • • • • •  -A . . . . .  . 
M. scrofulaceum CA • • • • • • • • • • • • • • • •  - • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •  - • • • • • TT . -GC • • • • •  
M. celat um . • . • . . . • . • . • . • • • . .  - . • . . . . • . •  T • • • • • • • • • • • • • • • • • • • • • • • • • • • •  - • • • •  T • • • -A . . . . .  . 
M. cookii . . . • . . . . . . . . • . • . •  T- • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •  - • •  T • • • •  A- . . . . . .  . 
01- 665 • • • • • • • • • • • • • • • • • •  - • • • • • • • • •  T • • • • • • • • • • • • • • • • • • • • • • • • • •  T . - . T  • •  CAC . - • •  T • • • •  
01- 6 6 4 • • • • • • • • • • • • • • • • • •  - • • • • • • • • •  T • • • • • • • • • • • • • • • • • • • • • • • • • • • •  - • • • •  T • CC-A • • • • • •  
0 1 - 6 3 6  C A  • • • • • • • • • • • • • • • •  - • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •  A • . . • .  - . • . . •  TT . -GC • • • • •  
0 1 - 63 3  • • • • • • • • • • • • • • • • • •  - • • • • • • • • •  T • • • • • • • • • • • • • • • • • • • • • • • • • • • •  - • •  T • • •  A . -TC • • • • •  
0 1-632  • • • • • • • • • • • • • • • • • •  - • • • • • • • • •  T • • • • • • • • • • • • • • • • • • • • • • • • • • • •  - • • • • • • •  C- • • • • • • •  
01-629  • • • • • • • • • • • • • • • • • •  - • • • • • • • • •  T • • • • • • • • • • • • • • • • • • • • • • • • • • • •  - • •  TCTT • •  - • • • • • • •  
01-628  • • • • • • • • • • • • • • • • • •  - • • • • • • • • •  T • • • • • • • • • • • • • • • • • • • • • • • • • • • •  - • • • • •  AT . - . . . . . .  . 
0 1 - 62 7  CA • • • • • • • • • • • • • • • •  - • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •  A • • • • •  - . • • • •  TT . -GC • • • • •  
2 7 6  
M .  tuberculosis TCTTG-TGGTGGAAAGCGCTTTAG- ---CGGTGTGGGATGAGCCCGCGGCCTATCAGCTTGTTGGTGGGGTGAC 
M. ul cerans • •  C . -G • • • • • • • • • • •  -- • • •  T . ---- • • • • • • • • • • • •  G • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •  ACA 
M. scrofulaceum C • • • •  - • • • • • • • • • . •  -- • • •  T . ---- • • • • . • . • • • • •  G • • • • • . • • • • • . . . • • • •  A . . • . . • . . • . . . .  T 
M. cel a t um . . . . . - . . . . . • • . . . •  -- • . .  T . ---- • • • • . • • • • • • •  G . . • • • . • • • • • • • • • • • • • • • • • • • • • • • • • •  T 
M. cookii 
0 1 - 6 65 
0 1 - 6 6 4 
0 1 - 6 3 6  
0 1 - 6 3 3  
01- 632 
01-629  
0 1 - 628 
01-627 
GTC • •  - • • • • • • • • • • •  -- • • •  T .  ---- • • • • • • • • • • • •  G • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •  T 
GTG • •  - • • • • • • • • • • •  -- • • •  T----G • • • • • • • • • • • • G • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •  T 
• GG • •  - • • • • • • • • • • •  -- • • •  T----G • • • • • • • • • • • •  G • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •  T 
C • • • •  - • • • • • • • • • • •  -- • • •  T----G • • • • • • • • • • • •  G • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •  T 
G • • • •  - • • • • • • • • • • •  -- • • •  T----G • • • • • • • • • • • •  G • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •  T 
GG • • •  - • • • • • • • • • • •  -- • • •  T----G • • • • • • • • • • • •  G • • • • • • • • • • • • • • • •  A . . . . . . • . . • • • . • .  T 
GT . GA-GA • • • • • • • • •  -- • • •  T----G • • • • • • • • • • • •  G • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • T 
GTG • •  - • • • • • • • • • • •  -- • • •  TT ---G • • • • • • • • • • • •  G • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •  T 
C • • • •  - • • • • • • • • • • •  -- • • •  T----G • • • • • • • • • • • •  G • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •  T 
Figure 25. Alignment of the 16S rDNA for the 8 CEI with cytopathic lipids in the 
hypervariable region A ( hp 129-277). Alignments were performed using the DNAstar 
program Megalign. CEI were compared with 24 other Mycobacterium species and 2 
Nocardia species. The first nucleotide shown corresponds to Escherichia coli 16S rRNA 
position 129. Nucleotides different from M tuberculosis are indicated. Dots represent 
identical nucleotides. Hyphens represent alignment gaps. 
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4 3 2  5 0 2  
M.  tuberculosis CCTCTTTCACCATCGACGAAGGTCCGGGTTCTC---TCGGATTGACGGTAGGTGGAGAAGAAGCACCGGCC 
M. ulcerans . . • . . . . • • . . . . . . . . . . . . . .  T • • • •  C . T  • •  --- • . . • • • • • • • • • • . . • • . . . • • • • • • • • . . • • • • •  
M. scrofula ceum • . • . • • . • . • • . • . • . . . . • • .  CT . A-----CTTT-GT • •  G • • . . • • • • • • • • • • . . • • • • • • • • • • . . . •  
M. cela tum . . • . . • . • . • • . • . . • . • . . .  C . G . C  • • • •  T • •  ---CG . TGG • • • • • • • • • • • • . . • • • • • • • • • • . . • • •  
M. cookii • . • . • • . • . . • . • . •  G • • • • •  CCGG . A . C . T . TGT- . TCTGG • • • • • • • • • • • . . . • • • • • • • • . • • • • • •  
0 1 - 6 65 • • • • • • • • • • • • • • •  G • • • • •  CCGGAT . C .  T .  TGTG . -CTGG • . • • • • • • • • • • • • • . • • . • • • • • • • • • .  
0 1 - 6 6 4  • • • • • • • • • • • • • • • • • • • • • •  C . --C . C-TCTG--- • • •  G • . • • • • • • • • • • • • • • • . • . • • • • • • • • • •  
0 1 - 63 6 • • • • • • • • • • • • • • • • • • • • • •  CT--CAC-- . TG-- -T . AG • • • • • • • . • • . . . • • • • • • • • • • . • • . • . •  
0 1 - 63 3  • • • • • • • • • • . . . • .  G • • • • •  CCAG • •  AC . T .  TGTC . TCTGG • • • • • • • • . • . . • • • • • • • • • • • . • . • . •  
0 1 - 63 2  • • • • • • • • • • • • • • • • • • • • • .  C . --C . C . T . TGG- -T • •  G • . • • • • • • • • • • • • • • • . • . • • • • • • • • • •  
0 1 - 62 9  • • • • • • • • • • • • • . . . • . • • • •  C .  --C . C .  T .  TGG--T • •  G • • • • • • • • • • • • • • • • • . • . • • • • • • • • • •  
0 1 - 62 8  • • • • • • . • . • • . • • • • • • • • • •  C .  --T . CGT . TG---T • •  G • • • • • • • • • • • • . . • . . • • • • • • • • • • • • •  
0 1 - 62 7  • • • • • • • • . • • • • • • • • • • • • •  CT--CAC . T .  TG-- -T . AG • • • • • • • • • • • • • • • . . . • • • • • • • • • • • •  
Figure 26. Alignment of the 16S rDNA for the 8 CEI with cytopathic lipids in the 
hypervariable region B (hp 430-495). Alignments were performed using the DNAstar 
program Megalign. CEI were compared with 24 other Mycobacterium species and 2 
Nocardia species. The first nucleotide shown corresponds to Escherichia coli 16S rRNA 
position 432. Nucleotides different from M tuberculosis are indicated. Dots represent 
identical nucleotides. Hyphens represent alignment gaps. 
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* 
* 
* 
* 
M. bovis 
M. tuberculosis 
'------- M. /eprae 
M. kansasii 
M. gastri 
M. intracellu/are 
* M. avium subsp. paratuberculosis 
M. scrofalaceum 
* 
01-636 
* 01-627 
,...._------- M. gordonae 
---------- M. simiae 
....------ M. ce/atum 
* 
* 
----------- 01-665 
..._ ______ 01-633 
M. cookii 
....------- 01-628 
------ 01-664 
.------ 01-632 
------- 01-629 
...._-------------- M. xenopi 
.----- M. terrae 
* ------ M. nonchromogenicum 
---- M. ph/ei 
...---- M.jlavescens 
M. smegmatis 
M. peregrinum 
* M. che/onae 
...------ Nocardia asteroides 
* ----------- Nocardiafarcinica 
0.01 
Figure 27. Phylogenetic tree constructed from 8 CEI with cytopathic ASLs. CEI 
1 6S rDNA sequences were aligned with 24 other Mycobacterium species' 1 6S rDNA. 
Nocardia species were used as outgroups to root the tree. Bootstrap values were 
calculated with 500 permutations. "*" indicates a bootstrap value > 50. 
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Bootstrap values were an indication of the statistical relevance of a particular branch, or 
node, of the tree. It was quite apparent from the phylogenetic analysis that none of these 
8 cytopathic CEI were closely related to M ulcerans. However, three distinct groups of 
relationship were present. Two of the CEI, 01 -636 and 01 -627, were closely related to 
M scrofulaceum. The other 6 CEI (01 -628, 01 -629, 01 -632, 01 -633, and 01 -664) showed 
relationship to M cookii and M celatum, with 0 1 -665 and 0 1 -633 being more closely 
related to M cookii. 
The phylogenetic tree analysis of the CEI is consistent with the BLAST analysis, 
further proving the accuracy of the tree. So, it was determined that the tree is an accurate 
representation of the relationships of the 16S rRNA genes for different Mycobacterium 
species, particularly the uncharacterized CEI. Therefore, due to the BLAST analysis and 
the phylogenetic tree analysis, the conclusion was made that these 8 CEI with cytopathic 
lipids are new, novel species of Mycobacterium which are not closely related to M 
ulcerans. 
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4. DISCUSSION 
I. Importance of Study: 
Previous work has identified mycolactone, a polyketide-derived macrolide, as a 
virulence determinant in M ulcerans (10). Many macrolides are important biologically 
active molecules especially as antibiotics, antifungals, antiparasitics, 
immunosuppressants, etc. Until the discovery of mycolactone in M ulcerans, macrolides 
had only been isolated from soil bacteria such as the Streptomyces and 
Saccharopolyspora species (19). M u/cerans is an environmental organism, and the 
presence of numerous IS elements in this organism has led to the suggestion that 
mycolactone may have been acquired by horizontal transfer from another environmental 
organism (34). If these environmental organisms were unable to colonize a human host, 
it is unlikely that their lipids would have been tested for cytopathicity. However 
evidence presented in this study, shows that mycolactone is quite restricted to M 
ulcerans, although other species of Mycobacterium do contain cytopathic lipids. Also, 
further findings from this study showed that a surprising number of uncharacterized 
mycobacteria from aquatic sources do produce cytotoxic lipids. Further examination of 
all Mycobacterium species would be necessary in order to say definitively that no other 
mycobacteria produce the macrolide, mycolactone. 
Polyketides have such a wide range of biological activity and are very useful 
agents. Also, with the increase in genome mapping, many more PKS genes have been 
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identified in organisms such as M tuberculosis (3). Therefore, the advent of new 
polyketides suggests new uses for such molecules especially in an age where 
microorganisms have increased resistance to almost all used antibiotics available. New 
drug discovery is becoming necessary in order to combat pathogens and polyketides have 
proven their worth biologically in the past (38). Therefore, a search for polyketides, 
such as mycolactone, in Mycobacterium species was an important study, although the 
results were negative. 
II. Problems with Cytopathic Lipid Analysis: 
Purification of mycolactone involved running M ulcerans AS Ls through a 
chromatotron or scrapping mycolactone off of a silica TLC plate. Therefore both 
chromatotron and preparative TLC methods were used to purify the cytopathic lipids. 
The solvent system determined to be best for mycolactone was chloroform-methanol 
(90: 10, vol/vol). Chloroform-methanol-water (90: 10: 1, vol/vol/vol) is used for running 
M ulcerans ASLs on TLC, however water is damaging to the chromatotron so it is left 
out during chromatotron use (9). However, several problems were encountered when 
using these separation methods. First, chromatotron separation was unsuccessful in 
separating these lipids due to the large numbers of lipid species and small quantity of 
individual lipids. Therefore the exact lipid species responsible for cytopathicity was not 
able to be isolated. Next preparative TLC was performed to try to achieve better 
separation. However problems arose again when trying to quantify these lipids. Most of 
these lipids were in such small amounts that they gave an undeterminable weight and the 
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L929 cell cytopathicity assays matched these results. All lipid species separated by 
preparative TLC had no cytopathic effect on L929 cells most likely due to the small 
amount of lipid present. Therefore, changes needed to be made to these separation 
methods. Mycolactone used a 1 mm glass silica plate (Alltech) for the separation of 
mycolactone. We originally used a 1 mm silica plate and it was unsuccessful. We then 
used a 2 mm silica glass plate (Alltech) in order to achieve better separation as well as 
using different combinations of chloroform-methanol. Separation with a 2 mm plate and 
using a different solvent system was more successful however it did not completely 
separate all lipid species. ASLs of the different Mycobacterium were able to be 
separated, but not into individual lipid species. Another problem that arose was more 
than one fraction would exhibit cytopathicity. So it was very likely that more than one 
lipid species was responsible for the cytopathic activity seen in the majority of the non­
M ulcerans species tested. Furthermore, when preparative TLC was used to further 
separate the chromatotron fractions the same quantitative problem arose. 
Chromatotron separation was successful in isolating one particular cytopathic 
lipid species, CEI O 1 -628. The CPA of this particular lipid species matched the CPA of 
whole ASLs from CEI 01 -628. Purity of a toxin is usually indicated by an increase in 
CPA when purified and this was not the case here. Several explanations can attribute to 
this occurrence. First, this lipid species may not be the only lipid responsible for the CPA 
seen. Secondly the lipid species may not be completely pure. However with either case 
we were able to determine that this lipid species is not mycolactone or core lactone. CEI 
01 -628 is one of the slow growing mycobacteria, and it usually takes three months for the 
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culture to reach late log phase growth. Furthermore the entire one liter culture is usually 
necessary to isolate the cytopathic lipid species; so working to isolate this lipid is difficult 
due to the growth time and quantity of lipid present. These constraints have also 
prohibited further identification tests to be performed on this lipid species. 
Many pathogenic my co bacteria contain lipid determinants of virulence, such as 
M tuberculosis and M leprae ( 6, 31 ). Although the Mycobacterium species in this 
study lack the production of mycolactone or the core lactone, these cytopathic lipids 
could be molecules of biological significance. However, due to the small quantity of 
lipids present, we were unable to determine the lipid(s) responsible. A possible solution 
for isolating these particular lipids is to employ different methods of separation. In this 
study, solvents systems that were used contained different combinations of chloroform­
methanol. However, different solvent systems using other solvents rather than just 
chloroform, methanol, and water should be tested. Solvent systems are difficult to work 
with and there are an abundance of solvents used for separating lipid species. 
Chloroform-methanol was used in this study due to its excellent separation of 
mycolactone. However, in this case, it may not be the best solvent for separation of the 
particular lipids in question. Mycolactone has a significant amount of cytopathic activity, 
therefore, the molecule was able to be isolated and assayed for cytopathicity. However, 
with the cytopathic lipids found here, most lipids were unable to be isolated, and assayed 
for cytopathicity due to lack of production of these lipids. These lipids lacked the 
potency that was seen with mycolactone therefore isolation was difficult, making any 
further analysis difficult as well. The lack of strong biological activity probably indicates 
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a lipid moiety that is only a secondary in virulence and is most likely not required for 
virulence. 
III. Further Studies Concerning Environmental Isolates: 
Included in this survey were 16  environmental mycobacteria isolated in the late 
1970s by Francoise Portaels in the Democratic Republic of Congo in regions endemic to 
M ulcerans (28). Although these 16  CEI were not identical to any of the 
Mycobacterium species at the time of isolation, many new diagnostic techniques have 
surfaced since then. Therefore, it was necessary for us to prove that these CEI were not 
species of M ulcerans that lack the genes for mycolactone production. The PCR test 
showed that none of the 16  CEI had 1S2404 or 1S2606 which indicated that none of these 
species were M ulcerans. Several of the CEI had cytopathic lipids and these species 
were further examined by 16S rRNA sequence analysis to determine their relationship to 
M ulcerans. The 16S rRNA has been shown to be an effective method of determining 
species identity for mycobacteria. The 16S rRNA gene contains hypervariable regions 
amongst highly conserved regions. It is these hypervariable regions that are used to 
determine species (21 ). We used primers designed to amplify two hypervariable regions, 
A and B, to determine if these 8 CEI with cytopathic lipids are new Mycobacterium 
species (1 6). A phylogenetic tree was constructed with the 16S rDNA obtained, 
determining the relationships of the 8 CEI to other mycobacteria. However, several 
bootstrap values were below 50. These low bootstrap values could be due to the short 
sequence length. Attempts at amplifying the entire 16S rRNA gene were made and were 
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unsuccessful. Therefore, if more sequence data was obtained the bootstrap values might 
improve. 
Only the 8 CEI with cytopathic lipids were phylogenetically analyzed. To further 
complete this study 1 6S rRNA sequence information should be obtained for the 
remaining CEI. Also, all of these CEI previously had biochemical tests performed on 
them, but in order to fully classify these species, further biochemical tests need to be 
performed (28). 
IV. Conclusions: 
From the results found in this study, several things were able to be concluded. 
First of all, none of the species tested in this study contain mycolactone or mycolactone 
congeners, based upon the cell assays. Furthermore, several species of Mycobacterium 
produce cytopathic polar lipids, but these lipids lack the potency seen with mycolactone 
and therefore were difficult to isolate. MS analysis on the one cytopathic lipid found 
( CEI O 1 -628) indicated that the cytopathic lipid is in fact not mycolactone or the core 
lactone. Furthermore, since CEI O 1 -628 cytopathic fraction produces vacuolization and 
most other species with cytopathic ASLs also exhibited vacuolization, it can be 
concluded that these cytopathic lipids are also not mycolactone or the core lactone. 
Finally, these uncharacterized environmental isolates of mycobacteria, isolated from 
aquatic environments endemic to M ulcerans infection, are not M ulcerans. However, 
they do represent new species of Mycobacterium. Some of these CEI are related to 
Mycobacterium species that are human pathogens, and their relevance as environmental 
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species would be interesting. However, further biochemical testing on these CEI is 
necessary to completely characterize these species. 
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